CN109045286A - 一种减小饮酒反应、降低酒精肝损伤的组合物及应用 - Google Patents

一种减小饮酒反应、降低酒精肝损伤的组合物及应用 Download PDF

Info

Publication number
CN109045286A
CN109045286A CN201810981848.5A CN201810981848A CN109045286A CN 109045286 A CN109045286 A CN 109045286A CN 201810981848 A CN201810981848 A CN 201810981848A CN 109045286 A CN109045286 A CN 109045286A
Authority
CN
China
Prior art keywords
vitamin
milligrams
drinking
reducing
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810981848.5A
Other languages
English (en)
Inventor
赵政
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micro Cell Life Technology (shenzhen) Co Ltd
Original Assignee
Micro Cell Life Technology (shenzhen) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micro Cell Life Technology (shenzhen) Co Ltd filed Critical Micro Cell Life Technology (shenzhen) Co Ltd
Priority to CN201810981848.5A priority Critical patent/CN109045286A/zh
Publication of CN109045286A publication Critical patent/CN109045286A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了一种减小饮酒反应、降低酒精肝损伤的组合物，包含如下原料：广谱组合消化酶、奶蓟草、N‑乙酰半胱氨酸、抗氧化物和活化复合维生素B；所述广谱组合消化酶包括双糖酶、淀粉酶、纤维素酶、脂肪酶和蛋白水解酶等；所述活化复合维生素B包括B1、活化B2、B3、B5、活化B6、活化B9、B7以及活化B12。同时公开了上述的减小饮酒反应、降低酒精肝损伤的组合物在解酒制剂中的应用，本发明配方为有针对性的功效营养素，按照一定的组合，有先后次序地使用，方便可行，能够起到减少饮酒反应，减低酒精肝损伤的良好效果，本发明的解酒有效率不低于80％。

Description

一种减小饮酒反应、降低酒精肝损伤的组合物及应用
技术领域
本发明属于保健品或者药品技术领域，更具体地说，本发明涉及一种减小饮酒反应、降低酒精肝损伤的组合物及应用。
背景技术
随着人民生活水平的迅速提高，酒类的消耗也大幅上升。2014年发表在《中华流行病学杂志》上对我国18～59岁就业流动人口12个月饮酒行为和模式的调查显示，成人男性饮酒率为71.9％，女性为24.7％；饮酒者日均酒精摄入量男性为18.7克，女性为4.1克；发生豪饮(按WHO定义为一次饮酒量男性超过50克，女性超过40克纯酒精)行为男性为71.2％，女性为33.1％。长期或过度饮酒引起的肝病的发病率呈迅速增长趋势。饮酒者往往是出现严重肝损害后才意识到之危害，为时已晚。目前亟待解决的问题是：怎样简易，有效地降低酒后肝脏受损的风险，并且减少酒后不适反应(宿醉)。
饮酒(酒精)造成器官伤害的机理是：酒精(乙醇)进入人体经胃肠道被吸收后，90％以上在肝脏代谢。乙醇在乙醇脱氢酶的作用下，变成乙醛；然后经乙醛脱氢酶转化为乙酸。乙酸最后被代谢成最终产物二氧化碳和水。乙醇具有神经麻醉作用，会产生兴奋、欣快、混沌、恍惚、错觉、协调障碍等现象，酒精上瘾，酒后胡言失态，酒后驾车事故都是这个原因，然而乙醛的健康的危害更严重，但比较隐蔽。乙醛具有肝脏毒性，会损坏肝细胞，导致脂肪肝，肝炎，继而进入肝硬化甚至肝癌等不可逆病变，同时乙醛也有直接的致癌作用，酒后体内乙醛存在的量和持续时间和乙醛生成(乙醇变为乙醛)速度和其被降解(乙醛变为乙酸)速度有关。前者是由乙醇脱氢酶的活性决定，后者是由乙醛脱氢酶的活性决定，过半数中国人乙醇脱氢酶活性过高，乙醛脱氢酶活性低，造成乙醛在体内存留时间长，浓度高，容易造成肝脏损伤。另外，乙醇本身在氧化过程中也会造成对肝脏的损伤，所以饮酒造成的肝损伤是多重的，复杂的，乙醛也是造成酒后身体，精神，甚至心理障碍的元凶。酒后的头痛，口干，嗜睡，眩晕，胃肠紊乱，焦虑等被称为宿醉，因为其发生在酒后几小时或第二天。这些针状是乙醛影响很多机体功能的表现，包括细胞产能受阻，代谢紊乱，酸中毒，大量自由基产生，激素分解紊乱等。乙醛的生成速度还和很多身体其它因素有关，如劳累，空腹，营养不良等都会使其加重。
目前没有简易，系统，有效的方法减少饮酒产生的宿醉和肝脏的损害。同时饮酒者重视不够，就医时往往已经有脂肪肝或更严重的肝脏损害，比如肝硬化，甚至已经演变为肝癌。所以需要一种有效减小饮酒反应、降低酒精肝损伤的方法。
发明内容
本发明的目的在于：针对现有技术的上述缺陷，提供一种减小饮酒反应、降低酒精肝损伤的组合物，能分解转化乙醇对身体的损害，同时又能保护肝脏，调理肠胃。
本发明的另一个目的在于：同时提供上述减小饮酒反应、降低酒精肝损伤的组合物在解酒用品中的应用，在饮酒前后按照次序进行服用，具有良好的效果。
为了实现上述发明目的，本发明提供了一种减小饮酒反应、降低酒精肝损伤的组合物，包含如下原料：广谱组合消化酶、奶蓟草、N-乙酰半胱氨酸、抗氧化物和活化复合维生素B。
优选地，所述广谱组合消化酶包括淀粉酶、α淀粉酶、葡糖淀粉酶、乳糖酶、蔗糖酶、麦芽糖酶、支链淀粉酶、纤维素酶、半纤维素酶、植酸酶、β葡聚糖酶、α半乳糖苷酶、半乳甘露聚糖酶、酸性蛋白酶、碱性蛋白酶、蛋白多肽酶复合物、脂肪酶、溶菌酶以及沙雷肽酶。
进一步地，所述广谱组合消化酶的剂量为：淀粉酶6-10万MWU、α淀粉酶80-120DU、葡糖淀粉酶25-35AGU、乳糖酶1500-2000ALU、蔗糖酶300-500SU、麦芽糖酶200-300MWU、支链淀粉酶20-30单位、纤维素酶400-600CU、半纤维素酶100-400HSU、植酸酶8-12PU、β葡聚糖酶18-22BGI、α半乳糖苷酶80-120AGSU、半乳甘露聚糖酶100-300HCU、酸性蛋白酶40-60SAPU、碱性蛋白酶40-60PC、蛋白多肽酶复合物10-30万DPPU、脂肪酶1000-2000FIPU、溶菌酶9-11万SHU以及沙雷肽酶2200-2700SPU。
进一步地，所述广谱组合消化酶的剂量为：淀粉酶8万MWU、α淀粉酶100DU、葡糖淀粉酶30AGU、乳糖酶1500ALU、蔗糖酶400SU、麦芽糖酶300MWU、支链淀粉酶25单位、纤维素酶500CU、半纤维素酶200HSU、植酸酶10PU、β葡聚糖酶20BGI、α半乳糖苷酶100AGSU、半乳甘露聚糖酶200HCU、酸性蛋白酶50SAPU、碱性蛋白酶50PC、蛋白多肽酶复合物20万DPPU、脂肪酶1500FIPU、溶菌酶10万SHU以及沙雷肽酶2500SPU。
优选地，所述活化复合维生素B包括维生素B1、活化维生素B2、维生素B3、维生素B5、活化维生素B6、活化维生素B9、维生素B7以及活化维生素B12。
优选地，所述活化复合维生素B的剂量为：维生素B1 40-60毫克、活化维生素B240-60毫克、维生素B3 80-120毫克、维生素B5 80-120毫克、活化维生素B6 40-60毫克、活化维生素B9 700-900微克、维生素B7 200-400毫克以及活化维生素B12 0.8-1.2毫克。
优选地，所述活化复合维生素B的剂量为：维生素B1 50毫克、活化维生素B2 50毫克、维生素B3 100毫克、维生素B5 100毫克、活化维生素B6 50毫克、活化维生素B9 800微克、维生素B7 300毫克以及活化维生素B12 1.0毫克。
优选地，所述抗氧化物包括：维生素C 150-300毫克、维生素A 950-1000国际单位、硒150-200微克、绿茶精华250-300毫克、银杏精华15-50毫克、维生素E 15-30国际单位。
优选地，所述奶蓟草的剂量为50-150毫克。
优选地，所述N-乙酰半胱氨酸的剂量为400-700毫克。
上述的减小饮酒反应、降低酒精肝损伤的组合物在解酒制剂中的应用，所述制剂的服用次序为：饮酒前服用广谱组合消化酶、奶蓟草和抗氧化物，酒后服用活化复合维生素B和N-乙酰半胱氨酸。
与现有技术相比，本发明具有如下有益效果：
本发明的广谱组合消化酶可以减少酒精对食物消化的影响，同时帮助排出有害物质，维护肠道的正常功能；维生素B对细胞能量产生，保护肝细胞，保护神经系统，维护乙醛脱氢酶的活性等都具有非常重要的作用；抗氧化物可以抵御酒精和其代谢产物产生的过多自由基，同时有保护中枢神经的作用；奶蓟草具有非常强的肝细胞保护和再生作用；N-乙酰半胱氨酸(NAC)是谷胱甘肽的前体，谷胱甘肽可以辅助乙醛脱氢酶，帮助肝脏解毒；这些有针对性的功效营养素，按照本发明的用量组合后，有先后次序地使用，是一个经济，方便可行，能够起到减少饮酒反应，减低酒精肝损伤的良好效果，本发明的解酒有效率不低于80％。
具体实施方式
为了使本发明的发明目的、技术方案及其技术效果更加清晰，以下通过具体实施方式，对本发明进一步详细说明。应当理解的是，本说明书中描述的具体实施方式仅仅是为了解释本发明，并非为了限定本发明。
实施例1(最优实施例)
一种减小饮酒反应、降低酒精肝损伤的组合物，由以下含量的原料组成：
1)广谱组合消化酶：
淀粉酶8万MWU，α淀粉酶100DU，葡糖淀粉酶30AGU，乳糖酶1500ALU，蔗糖酶400SU，麦芽糖酶300MWU，支链淀粉酶25单位，纤维素酶500CU，半纤维素酶200HSU，植酸酶10PU，β葡聚糖酶20BGI，α半乳糖苷酶100AGSU，半乳甘露聚糖酶200HCU，酸性蛋白酶50SAPU，碱性蛋白酶50PC，蛋白多肽酶复合物20万DPPU，脂肪酶1500FIPU，溶菌酶10万SHU，沙雷肽酶2500SPU；
2)奶蓟草：60毫克；
3)N-乙酰半胱氨酸：500毫克；
4)抗氧化物：维生素C 200毫克、维生素A1000国际单位，硒200微克，绿茶精华300毫克，银杏精华50毫克，维生素E 30国际单位；
5)活化复合维生素B：维生素B1 50毫克、活化维生素B2 50毫克、维生素B3 100毫克、维生素B5 100毫克、活化维生素B6 50毫克、活化5甲基四氢叶酸(维生素B9)800微克、生物素(维生素B7)300毫克以及活化维生素B12 1.0毫克。
上述组合物中可选的增加添加剂以制成制剂，制剂优选为胶囊，易服用和释放，一共制成4种胶囊制剂：广谱组合消化酶胶囊、奶蓟草抗氧化胶囊、活化复合维生素B胶囊和乙酰半胱氨酸胶囊。
本实施例制剂按照如下顺序进行服用：
饮酒前30分钟，服用含奶蓟草抗氧化胶囊2粒，广谱组合消化酶胶囊2粒；饮酒后2小时内，服用活化复合维生素B胶囊2粒，乙酰半胱氨酸胶囊2粒。
实施例2
一种减小饮酒反应、降低酒精肝损伤的组合物，由以下含量的原料组成：
1)广谱组合消化酶：
淀粉酶6万MWU、α淀粉酶120DU、葡糖淀粉酶35AGU、乳糖酶2000ALU、蔗糖酶300SU、麦芽糖酶200MWU、支链淀粉酶30单位、纤维素酶400CU、半纤维素酶100HSU、植酸酶12PU、β葡聚糖酶22BGI、α半乳糖苷酶120AGSU、半乳甘露聚糖酶100HCU、酸性蛋白酶40SAPU、碱性蛋白酶60PC、蛋白多肽酶复合物30万DPPU、脂肪酶1000FIPU、溶菌酶9万SHU、沙雷肽酶2200SPU；
2)奶蓟草：150毫克；
3)N-乙酰半胱氨酸：400毫克；
4)抗氧化物：维生素C 150毫克、维生素A980国际单位，硒150微克，绿茶精华250毫克，银杏精华35毫克，维生素E 20国际单位；
5)活化复合维生素B：维生素B1 60毫克、活化维生素B2 60毫克、维生素B3 80毫克、维生素B5 80毫克、活化维生素B6 40毫克、活化5甲基四氢叶酸(维生素B9)900微克、生物素(维生素B7)400毫克以及活化维生素B120.8毫克。
上述组合物中可选的增加添加剂以制成制剂，制剂优选为胶囊，易服用和释放，一共制成4种胶囊制剂：广谱组合消化酶胶囊、奶蓟草抗氧化胶囊、活化复合维生素B胶囊和乙酰半胱氨酸胶囊。
本实施例制剂按照如下顺序进行服用：
饮酒前30分钟，服用含奶蓟草抗氧化胶囊2粒，广谱组合消化酶胶囊2粒；饮酒后2小时内，服用活化复合维生素B胶囊2粒，乙酰半胱氨酸胶囊2粒。
实施例3
一种减小饮酒反应、降低酒精肝损伤的组合物，由以下含量的原料组成：
1)广谱组合消化酶：
淀粉酶10万MWU、α淀粉酶80DU、葡糖淀粉酶25AGU、乳糖酶1800ALU、蔗糖酶500SU、麦芽糖酶250MWU、支链淀粉酶20单位、纤维素酶600CU、半纤维素酶400HSU、植酸酶8PU、β葡聚糖酶18BGI、α半乳糖苷酶80AGSU、半乳甘露聚糖酶300HCU、酸性蛋白酶60SAPU、碱性蛋白酶40PC、蛋白多肽酶复合物10万DPPU、脂肪酶2000FIPU、溶菌酶11万SHU、沙雷肽酶2700SPU；
2)奶蓟草：50毫克；
3)N-乙酰半胱氨酸：700毫克；
4)抗氧化物：维生素C 300毫克、维生素A950国际单位，硒180微克，绿茶精华275毫克，银杏精华15毫克，维生素E 15国际单位；
5)活化复合维生素B：维生素B1 40毫克、活化维生素B2 40毫克、维生素B3 120毫克、维生素B5 120毫克、活化维生素B6 60毫克、活化5甲基四氢叶酸(维生素B9)700微克、生物素(维生素B7)200毫克以及活化维生素B12 1.2毫克。
上述组合物中可选的增加添加剂以制成制剂，制剂优选为胶囊，易服用和释放，一共制成4种胶囊制剂：广谱组合消化酶胶囊、奶蓟草抗氧化胶囊、活化复合维生素B胶囊和乙酰半胱氨酸胶囊。
本实施例制剂按照如下顺序进行服用：
饮酒前30分钟，服用含奶蓟草抗氧化胶囊2粒，广谱组合消化酶胶囊2粒；饮酒后2小时内，服用活化复合维生素B胶囊2粒，乙酰半胱氨酸胶囊2粒。
对比实验：
随机选取30名志愿者，年龄20-52岁，均饮用同组分含量同剂量的白酒，等待相同时间后，对其行为进行观察，并询问志愿者后，得出表1的对比实验数量统计表。本实验中分为5组，采用实施例1(组1)与另外4组方案进行比对，每组均由该30名志愿者使用，每组之间使用间隔时间为5天。
组1：本发明实施例1；
组2：仅在饮酒前30分钟，服用广谱组合消化酶胶囊；
组3：仅在饮酒后1小时，服用活化复合维生素B胶囊；
组4：仅在饮酒前30分钟，服用含奶蓟草抗氧化胶囊；
组5：与组1相比剂量减半；
收集实验者感受的信息分为两部分：1)酒精(乙醇)的神经兴奋作用、2)乙醚的中毒症状。
解酒效果判断标准：
有效：酒精神经兴奋作用明显减退，乙醛中毒症状基本消失；
缓解：酒精神经兴奋作用部分减退，乙醛中毒症状下降；
无效；酒精神经兴奋作用仅少量或没有减退，乙醛中毒症状未改变。
表1对比实验数量统计表
根据上表1中，有效率为有效数与总数的比，从表1中可以直观地看出组1的有效率为90％，有效率最好，组5中，用量降低一半，有效率也有63.3％。
同时本发明的其余实施例的有效率都不低于80％。
上面对本发明的实施例进行了描述，但是本发明并不局限于上述的具体实施方式，上述的具体实施方式仅仅是示意性的，而不是限制性的，本领域的普通技术人员在本发明的启示下，在不脱离本发明宗旨和权利要求所保护的范围情况下，还可做出很多形式，这些均属于本发明的保护之内。此外，尽管本说明书中使用了一些特定的术语，但这些术语只是为了方便说明，并不对本发明构成任何限制。

Claims (10)

1.一种减小饮酒反应、降低酒精肝损伤的组合物，其特征在于，包含如下原料：广谱组合消化酶、奶蓟草、N-乙酰半胱氨酸、抗氧化物和活化复合维生素B。
2.根据权利要求1所述的减小饮酒反应、降低酒精肝损伤的组合物，其特征在于，所述广谱组合消化酶包括淀粉酶、α淀粉酶、葡糖淀粉酶、乳糖酶、蔗糖酶、麦芽糖酶、支链淀粉酶、纤维素酶、半纤维素酶、植酸酶、β葡聚糖酶、α半乳糖苷酶、半乳甘露聚糖酶、酸性蛋白酶、碱性蛋白酶、蛋白多肽酶复合物、脂肪酶、溶菌酶以及沙雷肽酶。
3.根据权利要求2所述的减小饮酒反应、降低酒精肝损伤的组合物，其特征在于，所述广谱组合消化酶的剂量为：淀粉酶6-10万MWU、α淀粉酶80-120DU、葡糖淀粉酶25-35AGU、乳糖酶1500-2000ALU、蔗糖酶300-500SU、麦芽糖酶200-300MWU、支链淀粉酶20-30单位、纤维素酶400-600CU、半纤维素酶100-400HSU、植酸酶8-12PU、β葡聚糖酶18-22BGI、α半乳糖苷酶80-120AGSU、半乳甘露聚糖酶100-300HCU、酸性蛋白酶40-60SAPU、碱性蛋白酶40-60PC、蛋白多肽酶复合物10-30万DPPU、脂肪酶1000-2000FIPU、溶菌酶9-11万SHU以及沙雷肽酶2200-2700SPU。
4.根据权利要求3所述的减小饮酒反应、降低酒精肝损伤的组合物，其特征在于，所述广谱组合消化酶的剂量为：淀粉酶8万MWU、α淀粉酶100DU、葡糖淀粉酶30AGU、乳糖酶1500ALU、蔗糖酶400SU、麦芽糖酶300MWU、支链淀粉酶25单位、纤维素酶500CU、半纤维素酶200HSU、植酸酶10PU、β葡聚糖酶20BGI、α半乳糖苷酶100AGSU、半乳甘露聚糖酶200HCU、酸性蛋白酶50SAPU、碱性蛋白酶50PC、蛋白多肽酶复合物20万DPPU、脂肪酶1500FIPU、溶菌酶10万SHU以及沙雷肽酶2500SPU。
5.根据权利要求1所述的减小饮酒反应、降低酒精肝损伤的组合物，其特征在于，所述活化复合维生素B包括维生素B1、活化维生素B2、维生素B3、维生素B5、活化维生素B6、活化维生素B9、维生素B7以及活化维生素B12。
6.根据权利要求5所述的减小饮酒反应、降低酒精肝损伤的组合物，其特征在于，所述活化复合维生素B的剂量为：维生素B1 40-60毫克、活化维生素B2 40-60毫克、维生素B380-120毫克、维生素B5 80-120毫克、活化维生素B6 40-60毫克、活化维生素B9 700-900微克、维生素B7 200-400毫克以及活化维生素B12 0.8-1.2毫克。
7.根据权利要求5所述的减小饮酒反应、降低酒精肝损伤的组合物，其特征在于，所述活化复合维生素B的剂量为：维生素B1 50毫克、活化维生素B2 50毫克、维生素B3 100毫克、维生素B5 100毫克、活化维生素B6 50毫克、活化维生素B9 800微克、维生素B7 300毫克以及活化维生素B12 1.0毫克。
8.根据权利要求1所述的减小饮酒反应、降低酒精肝损伤的组合物，其特征在于，所述抗氧化物包括：维生素C 150-300毫克、维生素A 950-1000国际单位、硒150-200微克、绿茶精华250-300毫克、银杏精华15-50毫克以及维生素E 15-30国际单位。
9.根据权利要求1所述的减小饮酒反应、降低酒精肝损伤的组合物，其特征在于，所述奶蓟草的剂量为50-150毫克。
10.权利要求1-9任一项所述的减小饮酒反应、降低酒精肝损伤的组合物在解酒制剂中的应用，所述制剂的服用次序为：饮酒前服用广谱组合消化酶、奶蓟草和抗氧化物，酒后服用活化复合维生素B和N-乙酰半胱氨酸。
CN201810981848.5A 2018-08-27 2018-08-27 一种减小饮酒反应、降低酒精肝损伤的组合物及应用 Pending CN109045286A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810981848.5A CN109045286A (zh) 2018-08-27 2018-08-27 一种减小饮酒反应、降低酒精肝损伤的组合物及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810981848.5A CN109045286A (zh) 2018-08-27 2018-08-27 一种减小饮酒反应、降低酒精肝损伤的组合物及应用

Publications (1)

Publication Number Publication Date
CN109045286A true CN109045286A (zh) 2018-12-21

Family

ID=64757227

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810981848.5A Pending CN109045286A (zh) 2018-08-27 2018-08-27 一种减小饮酒反应、降低酒精肝损伤的组合物及应用

Country Status (1)

Country Link
CN (1) CN109045286A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111418850A (zh) * 2020-04-23 2020-07-17 吉林省慈卫归朴生物科技有限公司 一种解酒保肝组合物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1070574A (zh) * 1991-08-14 1993-04-07 丹羽耕三 低分子量植物组合物
JPH0940564A (ja) * 1995-07-26 1997-02-10 Taiyo Kagaku Co Ltd 悪酔予防改善用組成物
CN1593395A (zh) * 2003-09-09 2005-03-16 尹广宇 用乙酰半胱氨酸制成的解酒剂
CN101305799A (zh) * 2007-05-14 2008-11-19 尹广宇 用乙酰半胱氨酸酯制成的解酒剂
KR20160020807A (ko) * 2014-08-14 2016-02-24 (주)하이모 황국균 및 유산균 복합발효기술을 이용한 홍삼을 함유하는 발효 효소 식품의 제조 방법
CN108348566A (zh) * 2015-07-15 2018-07-31 尤尼根公司 用于治疗肝脏和维持肝脏健康的组合物、方法和药物组合物
CN109844106A (zh) * 2016-08-09 2019-06-04 维加努特里科技有限公司 新型葡萄糖氧化酶组合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1070574A (zh) * 1991-08-14 1993-04-07 丹羽耕三 低分子量植物组合物
JPH0940564A (ja) * 1995-07-26 1997-02-10 Taiyo Kagaku Co Ltd 悪酔予防改善用組成物
CN1593395A (zh) * 2003-09-09 2005-03-16 尹广宇 用乙酰半胱氨酸制成的解酒剂
CN101305799A (zh) * 2007-05-14 2008-11-19 尹广宇 用乙酰半胱氨酸酯制成的解酒剂
KR20160020807A (ko) * 2014-08-14 2016-02-24 (주)하이모 황국균 및 유산균 복합발효기술을 이용한 홍삼을 함유하는 발효 효소 식품의 제조 방법
CN108348566A (zh) * 2015-07-15 2018-07-31 尤尼根公司 用于治疗肝脏和维持肝脏健康的组合物、方法和药物组合物
CN109844106A (zh) * 2016-08-09 2019-06-04 维加努特里科技有限公司 新型葡萄糖氧化酶组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
加百列，等: "《如何选择营养素》", 30 June 2009, 中国社会出版社 *
王福根，等: "乙酰半胱氨酸对酒精性肝损伤大鼠细胞因子影响", 《中国公共卫生》 *
郭力，等: "《脂肪肝的预防与调养》", 30 September 2016, 中国中医药出版社 *
郭梅梅，等: "改善酒精性胰腺腺泡细胞分泌功能不足的分子靶点探讨", 《临床消化病杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111418850A (zh) * 2020-04-23 2020-07-17 吉林省慈卫归朴生物科技有限公司 一种解酒保肝组合物及其制备方法

Similar Documents

Publication Publication Date Title
CN101889679B (zh) 一种具有解酒保肝作用的组合物及其在食品、保健食品中的应用
US11464821B2 (en) Composition for reducing cancer cachexia or weight loss caused by anticancer drug therapy or radiation therapy comprising ginseng extract having increased ginsenoside Rg3 and Rh2
CN1856568B (zh) 发酵和培养的方法、植物发酵提取物、植物发酵提取物粉末以及含有植物发酵提取物的组合物
CN101953825B (zh) 一种解酒组合物及其在制备保健品中的应用
JP4917584B2 (ja) 可溶化蜂の子処理物、その製造方法、抗酸化剤、ａｃｅ阻害剤、血圧降下剤、皮膚繊維芽細胞増殖促進剤、疲労回復剤、血流改善剤、並びに可溶化蜂の子処理物を含有する医薬品、化粧品又は飲食品
CN104757560A (zh) 一种谷胱甘肽酵母酶解组合物及其制备方法
KR101447231B1 (ko) 숙취해소환의 제조 방법 및 상기 방법에 의하여 제조된 숙취해소환
CN104940240B (zh) 一种用于解酒护肝的益生菌制剂及其制备方法和应用
CN109045286A (zh) 一种减小饮酒反应、降低酒精肝损伤的组合物及应用
AU2014262427A1 (en) Compositions Comprising a Mixture of Bacteria Comprising Pediococcus and Lactobacillus and Methods for Decreasing the Effects of Alcohols
CN110122707A (zh) 一种解酒果汁饮料及其制备方法
CN103932180B (zh) 一种缓解压力及抗疲劳的保健食品及其二步发酵制备方法
JP2017201906A (ja) 栄養剤組成物及び栄養補助食品
RU2627128C2 (ru) Композиции, содержащие диаминоксидазу, для предотвращения симптомов похмелья
EP2789336B1 (en) Agent for preventing and/or treating hangover
CN111107854A (zh) 包含β-葡聚糖作为有效成分的宿醉解除用组合物或酒精性肝病预防、改善或治疗用组合物
CN104208692A (zh) 组合物在制备通便清肠产品中的应用
CN114272260B (zh) 一种海洋天然产物解酒保肝口服液、制备方法以及应用
CN109846042A (zh) 一类解酒的食品组合物
CN109576100A (zh) 一种能量型啤酒的制作工艺
CN116622559B (zh) 一种产乙醛脱氢酶的干酪乳杆菌、解酒益生菌组合物及其制备方法
JP7281927B2 (ja) 心拍数低減剤
CN102660445A (zh) 功能性低损伤养生酒
CN117378746A (zh) 一种基于天然产物的解酒果冻及其制备方法
CN104208694A (zh) 组合物在制备改善睡眠产品中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181221